SCHEMBL13745336

SCHEMBL13745336

O=C(NCc1ccccc1)c1ccccc1-c1cnc2[nH]cc(-c3ccoc3)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.61
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA4 P43681 1/20 0.49
DYRK1B Q9Y463 2/20 0.48
IGF1R P08069 1/20 0.47
MAP3K11 Q16584 2/20 0.47
ADORA2A P29274 1/20 0.46
AXL P30530 6/20 0.46
CCNT1 O60563 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CDK9 P50750 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
GSK3B P49841 1/20 0.45
SGK1 O00141 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8314436 0.88 CDK8 (0.59) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL8318330 0.87 CDK8 (0.58) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL8281969 0.86 DYRK1B (0.61) CDK8DYRK1BIGF1RMAP3K11AXL
SCHEMBL8316526 0.86 CDK8 (0.71) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL13745330 0.86 CDK8 (0.57) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL13746026 0.85 CDK8 (0.64) CDK8CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL13745546 0.85 CDK8 (0.56) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL8313356 0.85 CDK8 (0.56) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL8317282 0.82 CDK8 (0.59) CDK8IGF1RAXLCCNT1CCNA2
SCHEMBL8320558 0.81 CDK8 (0.64) CDK8IGF1RAXLCCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CDK8 360/4885CHRNB2 2191/4885CHRNB4 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.